Table 4. Toxicity related major adverse events (extended aromatase inhibitor vs. placebo).

Trial	Osteoporosis, %	Hot flushes, %	Arthralgia, %	Myalgia, %
MA 17	3.6 vs. 2.9	47.2 vs. 40.5	21.3 vs. 16.6	11.8 vs. 9.5
ABCSG 6a	0.8 vs. 1.1	39 vs. 22.4	–	–
NSABP-33	–	–	–	–
NSABP-42	–	–	–	–
DATA	21 vs. 16	–	58 vs. 53	–
LATER	73.2 vs. 64.1	–	74.5 vs. 63.5	33.5 vs. 19.9
IDEAL	10.2 vs. 7.5	11.8 vs. 10.5	14 vs. 13.2	–
MA 17R	11 vs. 6	38 vs. 37	53 vs. 50	28 vs. 25